https://www.selleckchem.com/pr....oducts/liraglutide.h
The combination of nsPEF treatment and PD-L1 blockade is a promising therapeutic strategy for liver cancer.We hypothesised that synthetic HDL nanoparticles carrying a gemcitabine prodrug and apolipoprotein A-II (sHDLGemA2) would target scavenger receptor-B1 (SR-B1) to preferentially and safely deliver gemcitabine into pancreatic ductal adenocarcinoma (PDAC). We designed, manufactured and characterised sHDLGemA2 nanoparticles sized ~130 nm, incorporating 20 mol% of a gemcitabine prodrug within the lipid bilayer, which strengthens on
Curtir
Comentario
Compartilhar
